AMSBIO Sponsor Poster Prize at Beatson Cancer Conference
AMSBIO, a provider of cutting-edge life science technologies and services for accelerating discovery in cancer research, has continued its sponsorship of the annual poster prize at the Beatson International Cancer Conference (7–10 July 2013).
The two winners of the Poster Prize for the best presented and most interesting posters, were this year named as Dr Thomas R. Cox and co-researchers** for their work on ‘Deep proteomic analysis of the hypoxic secretome lysyl oxidase as a critical mediator of metastatic lesion formation in bone’, and Dr Jean Albrengues & co-researchers*** for their work on ‘Production of LIF cytokine by cancer cells and fibroblasts contributes to the establishment of a pro-invasive tumour microenvironment’.
As one of Cancer Research UK’s core-funded institutes, the Beatson Institute (www.beatson.gla.ac.uk/) performs a programme of world-class science directed at understanding key aspects of cancer cell behaviour, and tries to translate these discoveries into new therapies and diagnostic/prognostic tools to help cancer patients. The Institute benefits from close interactions with the University of Glasgow, including strong links with the University’s Institute of Cancer Sciences.
AMSBIO is a rapidly growing company focused on the supply and development of products and technology for cancer research with emphasise on apoptosis, DNA damage and repair, and cancer cell function and behavior. AMSBIO supplies focused research products for cancer research that allow researchers to study cancer cell function and behavior including in angiogenesis, cell invasion and PARP and PARG research. Together with specifically designing assays for lead compound and genotoxic screening based on DNA damage and repair and cancer cell behavior, AMSBIO is establishing itself as a leading international provider of cancer research tools and services.
** Thomas R Cox1,2, Erwin M Schoof3, Demelza Bird2, Norain Ab Latif4, Antika Agrawal4, Holly R Evans4, Iain D Huggins4, Robin MH Rumney4, Georgina Lang2, Rune Linding3, Alsion Gartland4 and Janine T Erler1,2.
1 Biotech Research & Innovation Centre (BRIC), University of Copehagen, Denmark
2 Cancer Research UK Tumour Cell Signalling Unit, The Institute of Cancer Researh, London, UK
3 Cellular Signal Integration Group, Department of Systems Biology, Technical University of Denmark, Denmark.
4 The Mellanby Centre for Bone Research, The University of Sheffield, Sheffield, UK
*** Jean Albrengues1, Isabelle Bourget1, Catherine Pons1, Vincent Butet2, Sophie Tartare-Deckert3, Chloe Feral1, Guerrino Meneguzzi1 and Cedric Gaggioli1
1 INSERM, U1081, CRNS, UMR7284, Institute for Research on Cancer & Aging in Nice (IRCAN), University of Nice Sophia Antipolis, Medical School, 28 Avenue de Valombrose, F-06107, Nice, France.
2 Pathological anatomy & cytology laboratory, 270 Avenue Sainte-Marguerite, F-06200, Nice, France.
3 INSERM, U1065, Mediterranean Centre for Molecular Medicine (C3M), University of Nice Sophia Antipolis, Nice, France.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance